JAK/STAT Signaling

KMR-206 is a PARP7 inhibitor with an IC 50 of 13.7 nM.

WWQ-03-012 is a selective DESI2 inhibitor with an IC 50 of 47.3 nM.

AP4-43 is an orally active CLK1, CLK4, PI3K, DDR1, EGFR and NEK4 inhibitor.

ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC 50 of 7.0 nM for ROCK2 over ROCK1.

RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor ( IC 50 =15.1 and 22.7 nM).

IFN-α Receptor Recognition Peptide 1 acetate (IRRP1 acetate) is an amino acid synthetic peptide and also a regulator of IFN-α Receptor.

BP79 is a potent TSLP receptor inhibitor.

Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor.

Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor.

JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 ( IC 50 = 0.5 nM).

Turigrobart is a human monoclonal antibody targeting Epiregulin/EREG [1] .

Dulpatatug is a monoclonal antibody targeting ERBB2, which can be used for research on gastric cancer, breast cancer and non-small cell lung cancer.

Anti-Human/Mouse EGFR Antibody (7A7) ia an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab.

Rinumafusp alfa is a human monoclonal antibody targeting ERBB3/HER3.

LDC8201 is a selective, orally active, covalent inhibitor that targets EGFR and Her2 exon 20 insertion mutants.

ER121 (SGI-078) is an orally active non-toxic small molecule ErbB2 kinase inhibitor.

EGFR-IN-204 (Example 1) is a HER2 exon 20 mutation inhibitor with selectivity for wild-type EGFR.

EGFR/COX-2-IN-3 is a selective EGFR / COX-2 dual inhibitor with IC 50 values of 0.098 μM and 0.05 μM, respectively.

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate [1] .

Anti-Human/Mouse Amphiregulin Antibody (AR37) is an antibody targeting amphiregulin ( AREG ), with a K d value of 3.24 nM for the human protein and 6.40 nM for the mouse protein.

AZ14289671 is an orally active, blood-brain barrier-penetrant tyrosine kinase ( tyrosine kinase ) inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations ( EGFR Exon20Ins ), while largely sparing wild-type EGFR to reduce off-target toxicities such as rash and diarrhea.

NGI‑189 is a selective OST‑A inhibitor.

STA-013 is a EphB tyrosine kinase inhibitor.

STAT3-IN-52 hydrochloride is an orally active STAT3 inhibitor with a K i value of 2.42 μM.